Around $5.7M plus the $1.5M (TK shares that he sold) and $1.5M (R&D) so around $8.7M since last quarter.....
Ann: AstraZeneca to use new ResApp software in clinical study, page-46
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #